- O-3.97%
- world+12.72%
BlockBeats News, August 20th, UBS Group announced that it has raised Moderna's (MRNA.O) price target from $50 to $150.
Earlier reports stated that Moderna, in collaboration with Mercedez, has achieved significant success in a Phase III clinical trial of a personalized mRNA cancer vaccine targeting high-risk melanoma. This is the world's first mRNA cancer therapy to prove effective in a large-scale Phase III trial. Following the announcement, Moderna's stock price surged by nearly 177% in a single day.
Descargo de responsabilidad: El contenido actual proviene de perspectivas de terceros o es traducido directamente por IA a partir de perspectivas de terceros. CoinEx no garantiza la autenticidad, exactitud u originalidad del contenido, y no constituye ningún consejo de inversión. Los precios de las criptomonedas son altamente volátiles, por lo que debe ser consciente de los riesgos potenciales.
- MonedasPrecioCambio en 24H